Advertisement

Springer Seminars in Immunopathology

, Volume 15, Issue 4, pp 303–306 | Cite as

Introduction

  • Peter J. Lachmann
Article

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bordet J, Gengou O (1901) Sur l'existence de substances sensibilatrices dans la plupart des sérums antimicrobies. Ann Inst Pasteur 15:289–302Google Scholar
  2. Donaldson VH, Evans RR (1963) A biochemical abnormality in hereditary angioneurotic edema. Absence of serum inhibitor of C1 esterase. Am J Med 35:37–44PubMedGoogle Scholar
  3. Ecker EE, Pillemer L (1942) Complement. Ann N Y Acad Sci 43:63–83Google Scholar
  4. Gordon J, Whitehead HR, Wormall A (1926) The action of ammonia on complement: the fourth component. Biochem J 20:1028–1035Google Scholar
  5. Hourcade D, Holers VM, Atkinson JP (1989) The regulators of complement activation (RCA) gene clusters. Adv Immunol 45:381–416PubMedGoogle Scholar
  6. Lachmann PJ, Nicol PAE (1973) Reaction mechanism of the alternative pathway of complement fixation. Lancet i:465–467Google Scholar
  7. Lepow IH, Naff GB, Pensky J (1965) Mechanisms of activation of C′1 and inhibition of C′1 esterase. In: Wolstenholme GEW, Knight J (eds) Ciba Foundation Foundation on Complement. Churchill, London, pp 74–90Google Scholar
  8. Mayer MM (1961) Complement and complement fixation. In: Kabat EA, Mayer MM (eds) Kabat and Mayer's experimental immunochemistry, 2nd edn, Thomas, Springfield, Illinois, pp 133–24Google Scholar
  9. Müller-Eberhard HJ, Nilsson U (1960) Relation ofαβ1-glycoprotein of human serum to the complement system. J Exp Med III:217–234Google Scholar
  10. Nelson RA (1961) The properdin system: methods of measurement and inactivation of human complement components. In: Heidelberger M, Plescia OJ (eds) Immunochemical approaches to problems in microbiology. University Press, Rutgers, New Jersey, pp 295–303Google Scholar
  11. Nicol PAE, Lachmann PJ (1973) The alternate pathway of complement activation: the role of C3 and its inactivator (KAF). Immunology 24:259–275PubMedGoogle Scholar
  12. Pangburn MK, Müller-Eberhard HJ (1980) Relation of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med 152:1102PubMedGoogle Scholar
  13. Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw AC (1954) The properdin system and immunity. I. Demonstration and isolation of a new serum protein and its role in immune phenomena. Science 120:279–285PubMedGoogle Scholar
  14. Silverstein AM (1960) Essential hypocomplementemia. Report of a case. Blood 16:1338–1341PubMedGoogle Scholar
  15. Wiebauer K, Domdey H, Diggelmann H, Fey GH (1982) Isolation and analysis of genomic DNA clones encoding the third component of mouse complement. Proc Nat Acad Sci USA 79:7077–7081PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • Peter J. Lachmann
    • 1
  1. 1.Medical Research Council CentreCambridgeUK

Personalised recommendations